Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Arthritis Care Res (Hoboken) ; 69(3): 421-429, 2017 03.
Article in English | MEDLINE | ID: mdl-27483212

ABSTRACT

OBJECTIVE: Lowered pressure-pain thresholds have been demonstrated in adults with Ehlers-Danlos syndrome hypermobility type (EDS-HT), but whether these findings are also present in children is unclear. Therefore, the objectives of the study were to determine whether generalized hyperalgesia is present in children with hypermobility syndrome (HMS)/EDS-HT, explore potential differences in pressure-pain thresholds between children and adults with HMS/EDS-HT, and determine the discriminative value of generalized hyperalgesia. METHODS: Patients were classified in 1 of 3 groups: HMS/EDS-HT, hypermobile (Beighton score ≥4 of 9), and healthy controls. Descriptive data of age, sex, body mass index, Beighton score, skin laxity, and medication usage were collected. Generalized hyperalgesia was quantified by the average pressure-pain thresholds collected from 12 locations. Confounders collected were pain locations/intensity, fatigue, and psychological distress. Comparisons between children with HMS/EDS-HT and normative values, between children and adults with HMS/EDS-HT, and corrected confounders were analyzed with multivariate analysis of covariance. The discriminative value of generalized hyperalgesia employed to differentiate between HMS/EDS-HT, hypermobility, and controls was quantified with logistic regression. RESULTS: Significantly lower pressure-pain thresholds were found in children with HMS/EDS-HT compared to normative values (range -22.0% to -59.0%; P ≤ 0.05). When applying a threshold of 30.8 N/cm2 for males and 29.0 N/cm2 for females, the presence of generalized hyperalgesia discriminated between individuals with HMS/EDS-HT, hypermobility, and healthy controls (odds ratio 6.0). CONCLUSION: Children and adults with HMS/EDS-HT are characterized by hypermobility, chronic pain, and generalized hyperalgesia. The presence of generalized hyperalgesia may indicate involvement of the central nervous system in the development of chronic pain.


Subject(s)
Chronic Pain/etiology , Ehlers-Danlos Syndrome/complications , Hyperalgesia/etiology , Joint Instability/complications , Joints/physiopathology , Pain Threshold , Adolescent , Adult , Age Factors , Belgium , Biomechanical Phenomena , Case-Control Studies , Child , Chronic Pain/diagnosis , Chronic Pain/physiopathology , Diagnosis, Differential , Discriminant Analysis , Ehlers-Danlos Syndrome/diagnosis , Ehlers-Danlos Syndrome/physiopathology , Ehlers-Danlos Syndrome/psychology , Female , Humans , Hyperalgesia/diagnosis , Hyperalgesia/physiopathology , Joint Instability/diagnosis , Joint Instability/physiopathology , Joint Instability/psychology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Netherlands , New South Wales , Odds Ratio , Pain Measurement , Predictive Value of Tests , Risk Factors , Young Adult
2.
Horm Res Paediatr ; 79(6): 333-40, 2013.
Article in English | MEDLINE | ID: mdl-23735642

ABSTRACT

OBJECTIVE: Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta (OI), commenced before three years of age. METHODS: A retrospective review of 17 patients with moderate-to-severe OI. Development, anthropometry, fracture history, bone mineral density (BMD) and biochemistry were collected at baseline, 12 and 24 months. RESULTS: Four had OI type I, eleven had type III, one OI-FKBP10 type and one OI type V. Mean age at start of pamidronate was 14 ± 11 months. Pamidronate ranged from 6 to 12 mg/kg/year. No adverse reaction apart from fever and vomiting was noted. Long bone fracture decreased from a mean of 10.4/year to 1.2/year after 12 months and 1.4/year after 24 months (p = 0.02). Lumbar spine age- and height-matched BMD Z-scores increased (p < 0.005). Sixteen with vertebral compression fractures at baseline all showed improved vertebral shape (p < 0.001). Concavity index, likewise, improved (p < 0.005). Motor milestones compared to historical data show earlier attainment in rolling over, crawling, pulling to stand and walking independently but not sitting. CONCLUSION: Cyclic intravenous pamidronate, started under 3 years of age in children with moderate-to-severe OI, was well tolerated and associated with an increase in lumbar spine BMD, reduced fracture frequency, vertebral remodelling and attainment of motor milestones at an earlier age.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Diphosphonates/administration & dosage , Fractures, Bone/prevention & control , Osteogenesis Imperfecta/drug therapy , Bone Density , Child, Preschool , Female , Humans , Infant , Infusions, Intravenous , Lumbar Vertebrae/anatomy & histology , Lumbar Vertebrae/physiology , Male , Motor Skills , Pamidronate , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...